Workman P
CRC Department of Medical Oncology, University of Glasgow, Bearsden, UK.
Int J Radiat Oncol Biol Phys. 1992;22(4):631-7. doi: 10.1016/0360-3016(92)90493-2.
The design, development, and application of bioreductive antitumor agents in a rational way requires a detailed understanding of the mechanisms involved in their action. In addition to measuring and manipulating tumor hypoxia, we need to elucidate the particulars of the activation versus bioprotection pathways and the nature and properties of the participating enzymes. These areas are reviewed with particular reference to the development of novel quinone, nitro and N-oxide bioreductives.
以合理的方式设计、开发和应用生物还原抗肿瘤药物需要详细了解其作用机制。除了测量和控制肿瘤缺氧外,我们还需要阐明激活与生物保护途径的具体情况以及参与酶的性质和特性。本文特别参考新型醌类、硝基和N-氧化物生物还原剂的开发对这些领域进行了综述。